Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2450/2015.0096-15 http://scihub22266oqcxt.onion/10.2450/2015.0096-15 C4781787!4781787!26710352     free     free     free       Blood+Transfus 2016 ; 14 (2): 175-84 Nephropedia Template TP {{tp|p=26710352|t=2016. The evolution of anticoagulant therapy |pdf=|usr=}}{{26710352}} gab.com Text The evolution of anticoagulant therapy JO: Blood Transfus http://www.kidney.de/pget.php?&tw=1&pmid=26710352 #FOAvip Arterial and venous thromboembolism are leading causes of morbidity and mortality around the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight heparins) and vitamin K antagonists have been the leading therapeutic medical options for the treatment and prevention of thromboembolic disorders. Nevertheless, the many limitations of these traditional anticoagulants have fuelled the search for novel agents over the past 15 years, and a new class of oral anticoagulants that specifically target activated factor X and thrombin has been developed and is now commercially available. In this narrative review, the evolution of anticoagulant therapy is summarised, with a focus on newer oral anticoagulants. Twit Text FOAVip The evolution of anticoagulant therapy ????Blood Transfus http://www.kidney.de/pget.php?&tw=1&pmid=26710352 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26710352 #FOAvip English Wikipedia <ref>{{Cite pmid|26710352}}</ref> The evolution of anticoagulant therapy #MMPMID26710352 Franchini M; Liumbruno GM; Bonfanti C; Lippi G Blood Transfus 2016[Mar]; 14 (2): 175-84 PMID26710352show ga Arterial and venous thromboembolism are leading causes of morbidity and mortality around the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight heparins) and vitamin K antagonists have been the leading therapeutic medical options for the treatment and prevention of thromboembolic disorders. Nevertheless, the many limitations of these traditional anticoagulants have fuelled the search for novel agents over the past 15 years, and a new class of oral anticoagulants that specifically target activated factor X and thrombin has been developed and is now commercially available. In this narrative review, the evolution of anticoagulant therapy is summarised, with a focus on newer oral anticoagulants. äThe evolution of anticoagulant therapy (epmc).pdf DeepDyve Pubget Overpricing